两剂BNT162b2 mRNA新冠疫苗接种180天后亚洲新冠病毒初感染者体内强大的SARS-CoV-2抗体反应
Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine.
作者信息
Lau Chin-Shern, Phua Soon Kieng, Liang Ya-Li, Oh Helen May-Lin, Aw Tar-Choon
机构信息
Department of Laboratory Medicine, Changi General Hospital, Singapore 529889, Singapore.
Department of Infectious Diseases, Changi General Hospital, Singapore 529889, Singapore.
出版信息
Vaccines (Basel). 2021 Oct 25;9(11):1241. doi: 10.3390/vaccines9111241.
BACKGROUND
Subjects with previous COVID-19 have augmented post-vaccination responses. However, the antibody response in COVID-naïve subjects from Southeast Asia is not well known.
METHODS
77 COVID-naïve vaccinees were tested with a full antibody panel [spike antibodies (total (T-Ab), IgG, IgM) and neutralizing antibodies (N-Ab)] pre-vaccination, 10 days after dose 1, and 20/40/60/90/120/150/180 days after dose 2.
RESULTS
10 days after dose 1, 67.6% (48/71)/69.0% (49/71) were T-Ab/IgG positive; only 15.5% (11/71)/14.1% (10/71) were N-Ab/IgM positive. While all (100%) subjects had brisk T-Ab, IgG and N-Ab antibody responses 20 days after complete vaccination, only 79.1% (53/67) were IgM positive. At 180 days ( = 8), T-Ab/IgG/N-Ab were still reactive (lowest T-Ab 186 U/mL, IgG 617 AU/mL, N-Ab 0.39 µg/mL), but IgM was negative in all samples. Spike antibody thresholds of T-Ab 74.1 U/mL (r = 0.95) and IgG 916 AU/mL (r = 0.95) corresponded to N-Ab reactivity (>0.3 µg/mL). Non-linear regression analysis showed that N-Ab would decrease to 0.3 µg/mL by 241 days, whereas T-Ab/IgG would need 470/163 days to reach titers of T-Ab/IgG associated with a N-Ab 0.3 µg/mL (76.4 U/mL and 916 AU/mL respectively).
CONCLUSIONS
The antibody responses of T-Ab, IgG and N-Ab remain high and durable even at 180 days. N-Ab titers are expected to remain reactive up to 241 days post-vaccination.
背景
既往感染过新型冠状病毒肺炎（COVID-19）的受试者接种疫苗后的反应增强。然而，东南亚未感染过COVID-19的受试者的抗体反应尚不清楚。
方法
对77名未感染过COVID-19的疫苗接种者在接种前、第1剂疫苗接种后10天以及第2剂疫苗接种后20/40/60/90/120/150/180天进行了全抗体检测[刺突抗体（总抗体（T-Ab）、IgG、IgM）和中和抗体（N-Ab）]。
结果
第1剂疫苗接种后10天，67.6%（48/71）/69.0%（49/71）的受试者T-Ab/IgG呈阳性；只有15.5%（11/71）/14.1%（10/71）的受试者N-Ab/IgM呈阳性。在完成疫苗接种20天后，所有（100%）受试者的T-Ab、IgG和N-Ab抗体反应均活跃，只有79.1%（53/67）的受试者IgM呈阳性。在180天（n = 8）时，T-Ab/IgG/N-Ab仍有反应（最低T-Ab为186 U/mL，IgG为617 AU/mL，N-Ab为0.39 µg/mL），但所有样本中的IgM均为阴性。T-Ab阈值74.1 U/mL（r = 0.95）和IgG阈值916 AU/mL（r = 0.95）对应N-Ab反应性（>0.3 µg/mL）。非线性回归分析显示，N-Ab在241天时将降至0.3 µg/mL，而T-Ab/IgG分别需要470/163天才能达到与N-Ab 0.3 µg/mL（分别为76.4 U/mL和916 AU/mL）相关的T-Ab/IgG滴度。
结论
即使在180天时，T-Ab、IgG和N-Ab的抗体反应仍然很高且持久。预计N-Ab滴度在疫苗接种后241天内仍有反应。
Zotero 插件